Display options
Cite
Woon SA, Manning L, Moore BR. Antimalarials for children with Plasmodium vivax infection: Current status, challenges, and research priorities. Parasitol Int. 2021;87:102512doi: 10.1016/j.parint.2021.102512.
Woon, S. A., Manning, L., & Moore, B. R. (2021). Antimalarials for children with Plasmodium vivax infection: Current status, challenges, and research priorities. Parasitology international, 87102512. https://doi.org/10.1016/j.parint.2021.102512
Woon, Sze-Ann, et al. "Antimalarials for children with Plasmodium vivax infection: Current status, challenges, and research priorities." Parasitology international vol. 87 (2021): 102512. doi: https://doi.org/10.1016/j.parint.2021.102512
Woon SA, Manning L, Moore BR. Antimalarials for children with Plasmodium vivax infection: Current status, challenges, and research priorities. Parasitol Int. 2021 Nov 14;87:102512. doi: 10.1016/j.parint.2021.102512. Epub 2021 Nov 14. PMID: 34785369.
Copy Download .nbib Format: NLM
Share it on

Parasitol Int. 2021 Nov 14;87:102512. doi: 10.1016/j.parint.2021.102512. Epub 2021 Nov 14.

Antimalarials for children with Plasmodium vivax infection: Current status, challenges, and research priorities.

Parasitology international

Sze-Ann Woon, Laurens Manning, Brioni R Moore

Affiliations

  1. Medical School, University of Western Australia, Perth, Western Australia, Australia.
  2. Medical School, University of Western Australia, Perth, Western Australia, Australia; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
  3. Medical School, University of Western Australia, Perth, Western Australia, Australia; Curtin Medical School, Curtin University, Perth, Western Australia, Australia; Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia. Electronic address: [email protected].

PMID: 34785369 DOI: 10.1016/j.parint.2021.102512

Abstract

The aim of this narrative review is to summarise efficacy and pharmacokinetic data for Plasmodium vivax in children. The burden of P. vivax malaria in children continues to remain a significant public health issue, and the need for improved treatment regimens for this vulnerable population is critical. Relapse after re-activation of dormant liver-stage hypnozoites poses additional challenges for treatment, elimination, and control strategies for P. vivax. Whilst it is recognised that paediatric pharmacology may be significantly influenced by anatomical and physiological changes of childhood, dosing regimens often continue to be extrapolated from adult data, highlighting the need for antimalarial dosing in children to be evaluated in early phase clinical trials. This will ensure that globally recommended treatment regimens do not result in suboptimal dosing in children. Furthermore, the development of affordable paediatric formulations to enhance treatment acceptability and widespread G6PD testing to facilitate use of anti-hypnozoite treatment such as primaquine and tafenoquine, should be further prioritised. As the world prepares for malaria elimination, a renewed focus on P. vivax malaria provides an ideal opportunity to harness momentum and ensure that all populations, including children have access to safe, efficacious, and correctly dosed antimalarial therapies.

Copyright © 2021 Elsevier B.V. All rights reserved.

Keywords: Artemisinin combination therapy; Paediatrics; Pharmacokinetics; Pharmacotherapy; Plasmodium vivax; Primaquine, chloroquine, tafenoquine

Publication Types